Search
Tepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalIn February 2022, tepotinib was approved for use in Europe.[L42200]
Linaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigationalLinaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist. Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activato...
Phenaridine
go.drugbank.com/drugs/DB09178ExperimentalIllicitFentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue
Baloxavir marboxil
go.drugbank.com/drugs/DB13997ApprovedInvestigational[L4779] It was also approved by the European Commission on January 7, 2021.[L45241]
Budesonide
go.drugbank.com/drugs/DB01222ApprovedInvestigationalBudesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. Budesonide was granted FDA approval o...
Briakinumab
go.drugbank.com/drugs/DB05459InvestigationalAs of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.
Tofisopam
go.drugbank.com/drugs/DB08811InvestigationalAlthough Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe.
Irofulven
go.drugbank.com/drugs/DB05786InvestigationalPhase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.
Bictegravir
go.drugbank.com/drugs/DB11799ApprovedInvestigationalBictegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used in the treatment of HIV-1 infection. It is not administered alone; it is available in fixed-dose combination tablets, with teno...
Cilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalSARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain ...